目的 评价茵陈蒿汤（Yinchenhao Decoction，YCHD）治疗阳黄证的临床疗效，发现药效物质基础。方法 基于方证代谢组学方法，揭示临床阳黄证的代谢轮廓及生物标记物，评价YCHD治疗阳黄证的临床疗效；在显效状态下，利用中药血清药物化学技术探究YCHD体内成分，与效应标记物进行相关性分析，确定药效物质基础。结果 鉴定了阳黄证34个尿液生物标记物，其中24个生物标记物在YCHD治疗后回调；鉴定了显效状态下26个血中移行成分，其中3个成分为YCHD治疗阳黄证的药效物质基础。结论YCHD通过下调苯丙酮酸、苯乙酸影响苯丙氨酸代谢通路治疗阳黄证，其药效物质基础为5-脱羟基-6-去甲氧基茵陈色原酮、蕨内酰胺及大黄酸-8-O-β-D-葡萄糖苷。

Objective To evaluate the clinical efficacy of Yinchenhao Decoction (茵陈蒿汤, YCHD) in treating Yanghuang syndrome (YHS) and to discover the effective substance. Methods Chinmedomics reveals the metabolic profile and biomarkers of clinical YHS, and evaluates the clinical efficacy of YCHD in treating YHS. Under the condition of efficacy, the serum pharmacochemistry of traditional Chinese medicine was utilized to explore the components of YCHD in vivo, and a correlation analysis was conducted with the effect biomarkers to determine the effective substance. Results A total of 34 urinary biomarkers were identified in YHS, of which 24 biomarkers were adjusted after treatment with YCHD, the 26 constituents absorbed into blood were identified under the condition of efficacy, of which three constituents were analyzed as the effective substance of YCHD in treating YHS. Conclusion YCHD can affect phenylalanine metabolic pathway by down regulating phenylpyruvic acid and phenylacetic acid in the treatment of YHS. Its effective substances are 5-dehydroxy-6-demethylcapillarisin, pterolactam, and rhein-8-O-β-D-glucopyranoside.

R285

黑龙江省中医药管理局青年中医药科研课题（ZHY2023-211）;黑龙江中医药大学校科研基金项目（2024XJJ-QNCX007）;国家自然科学基金青年项目（82204798）